Progress in vaccine development for infectious diseases—a Keystone Symposia report-Reference-Cited by-同舟云学术

Progress in vaccine development for infectious diseases—a Keystone Symposia report

Published:2023-04-05 Issue:1 Volume:1524 Page:65-86
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:Annals of the New York Academy of Sciences

Author:

Cable Jennifer¹,Graham Barney S.²,Koup Richard A.³,Seder Robert A.³,Karikó Katalin⁴,Pardi Norbert⁵,Barouch Dan H.⁶,Sharma Bhawna⁷,Rauch Susanne⁸,Nachbagauer Raffael⁹¹⁰,Forsell Mattias N. E.¹¹,Schotsaert Michael⁹¹²,Ellebedy Ali H.¹³,Loré Karin¹⁴,Irvine Darrell J.¹⁵¹⁶¹⁷,Pilkington Emily¹⁸¹⁹,Tahtinen Siri²⁰,Thompson Elizabeth A.²¹,Feraoun Yanis²²,King Neil P.²³,Saunders Kevin²⁴,Alter Galit¹⁷,Moin Syed M.³,Sliepen Kwinten²⁵,Karlsson Hedestam Gunilla B.²⁶,Wardemann Hedda²⁷,Pulendran Bali²⁸,Doria‐Rose Nicole A.³,He Wan‐Ting¹⁶²⁹,Juno Jennifer A.¹⁸,Ataca Sila³,Wheatley Adam K.¹⁸,McLellan Jason S.³⁰,Walker Laura M.³¹³²,Lederhofer Julia³,Lindesmith Lisa C.³³,Wille Holger³⁴,Hotez Peter J.³⁵³⁶³⁷³⁸,Bekker Linda‐Gail³⁹

Affiliation:

1. PhD Science Writer New York New York USA

2. Morehouse School of Medicine Atlanta Georgia USA

3. Vaccine Research Center, National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland USA

4. BioNTech SE Mainz Germany

5. Department of Microbiology, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

6. Harvard Medical School Boston Massachusetts USA

7. Gilead Sciences Foster City California USA

8. CureVac AG Tübingen Germany

9. Department of Microbiology Icahn School of Medicine at Mount Sinai New York New York USA

10. Moderna Cambridge Massachusetts USA

11. Department of Clinical Microbiology Umeå University Umeå Sweden

12. Global Health and Emerging Pathogens Institute Icahn School of Medicine at Mount Sinai New York New York New York USA

13. Department of Pathology and Immunology; Center for Vaccines and Immunity to Microbial Pathogens; and The Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs Washington University School of Medicine St. Louis Missouri USA

14. Department of Medicine Solna Karolinska Institutet and Karolinska University Hospital Stockholm Sweden

15. Koch Institute for Integrative Cancer Research; Department of Biological Engineering; and Department of Materials Science and Engineering Massachusetts Institute of Technology Cambridge Massachusetts USA

16. Consortium for HIV/AIDS Vaccine Development (CHAVD) Scripps Research Institute La Jolla California USA

17. Ragon Institute of Massachusetts General Hospital Massachusetts Institute of Technology and Harvard University Cambridge Massachusetts USA

18. Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity The University of Melbourne Melbourne Victoria Australia

19. Department of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences Monash University Melbourne Victoria Australia

20. Genentech South San Francisco California USA

21. Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland USA

22. Université Paris‐Saclay, Inserm, CEA, Center for Immunology of Viral Auto‐Immune, Hematological and Bacterial Diseases (IMVA‐HB/IDMIT) Fontenay‐aux‐Roses France

23. Department of Biochemistry and Institute for Protein Design University of Washington Seattle Washington USA

24. Human Vaccine Institute Duke University Durham North Carolina USA

25. Department of Medical Microbiology, Amsterdam UMC University of Amsterdam Amsterdam Netherlands

26. Department of Microbiology, Tumor and Cell Biology Karolinska Institutet Stockholm Sweden

27. Division of B Cell Immunology German Cancer Research Center Heidelberg Germany

28. Institute for Immunity, Transplantation and Infection; Department of Pathology; and Department of Microbiology & Immunology, Stanford University School of Medicine Stanford University Stanford California USA

29. Department of Immunology and Microbiology and IAVI Neutralizing Antibody Center The Scripps Research Institute La Jolla California USA

30. Department of Molecular Biosciences University of Texas at Austin Austin Texas USA

31. Adimab, LLC Lebanon New Hampshire USA

32. New Hampshire and Adagio Therapeutics, Inc. Waltham Massachusetts USA

33. Department of Epidemiology University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

34. Centre for Prions and Protein Folding Diseases and Department of Biochemistry University of Alberta Edmonton Alberta Canada

35. Texas Children's Center for Vaccine Development, Departments of Pediatrics and Molecular Virology & Microbiology, National School of Tropical Medicine Baylor College of Medicine Houston Texas USA

36. James A Baker III Institute for Public Policy Rice University Houston Texas USA

37. Department of Biology Baylor University Waco Texas USA

38. Hagler Institute for Advanced Study and Scowcroft Institute of International Affairs Bush School of Government and Public Service Texas A&M University College Station Texas USA

39. Desmond Tutu HIV Centre University of Cape Town Cape Town South Africa

Abstract

AbstractThe COVID‐19 pandemic has taught us many things, among the most important of which is that vaccines are one of the cornerstones of public health that help make modern longevity possible. While several different vaccines have been successful at stemming the morbidity and mortality associated with various infectious diseases, many pathogens/diseases remain recalcitrant to the development of effective vaccination. Recent advances in vaccine technology, immunology, structural biology, and other fields may yet yield insight that will address these diseases; they may also help improve societies’ preparedness for future pandemics. On June 1–4, 2022, experts in vaccinology from academia, industry, and government convened for the Keystone symposium “Progress in Vaccine Development for Infectious Diseases” to discuss state‐of‐the‐art technologies, recent advancements in understanding vaccine‐mediated immunity, and new aspects of antigen design to aid vaccine effectiveness.

Funder

National Institutes of Health

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/nyas.14975

Reference175 articles.

1. World Health Organization. (2018).https://www.who.int/news‐room/fact‐sheets/detail/the‐top‐10‐causes‐of‐death

2. Immunization. (2023). https://www.unicef.org/immunization

3. Prototype pathogen approach for pandemic preparedness: world on fire

4. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationally seeded computational protein design of ɑ-helical barrels;Nature Chemical Biology;2024-06-20

2. LEVERAGING THE SUCCESS OF MRNA LIPID NANOPARTICLE VACCINE IN COVID-19 TREATMENT: A NARRATIVE REVIEW ON ITS POTENTIAL APPLICATION IN MALARIA TREATMENT;International Journal of Applied Pharmaceutics;2024-06-07

3. Oral tolerance to systemic vaccination remains intact without RORγt expression in regulatory T cells;iScience;2023-12

4. Rationally seeded computational protein design;2023-08-26